CYP17 inhibitors in prostate cancer: latest evidence and clinical potential
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CYP17 inhibitors in prostate cancer: latest evidence and clinical potential
Authors
Keywords
-
Journal
Therapeutic Advances in Medical Oncology
Volume 8, Issue 4, Pages 267-275
Publisher
SAGE Publications
Online
2016-04-20
DOI
10.1177/1758834016642370
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Does Gleason score (GS) predict efficacy of abiraterone acetate (AA) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)? An analysis of AA phase 3 trials.
- (2017) Karim Fizazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients
- (2015) X. S. Xu et al. CLINICAL CANCER RESEARCH
- Impact of Bone-targeted Therapies in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302
- (2015) Fred Saad et al. EUROPEAN UROLOGY
- The oral CYP17-Lyase (L) inhibitor VT-464 in patients with CRPC.
- (2015) Johann Sebastian De Bono et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5
- (2015) Karim Fizazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery and Development of Galeterone (TOK-001 or VN/124-1) for the Treatment of All Stages of Prostate Cancer
- (2015) Vincent C. O. Njar et al. JOURNAL OF MEDICINAL CHEMISTRY
- Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial
- (2015) Fred Saad et al. LANCET ONCOLOGY
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
- (2015) Zhenfei Li et al. NATURE
- Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
- (2015) H H Cheng et al. PROSTATE CANCER AND PROSTATIC DISEASES
- CYP17A1 inhibitors in castration-resistant prostate cancer
- (2015) Lissette Gomez et al. STEROIDS
- Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
- (2015) Emmanuel S. Antonarakis et al. JAMA Oncology
- Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
- (2014) MarkN Stein et al. ASIAN JOURNAL OF ANDROLOGY
- Abiraterone for Treatment of Metastatic Castration-resistant Prostate Cancer: a Systematic Review and Meta-analysis
- (2014) Zhi-Rui Zhou et al. Asian Pacific Journal of Cancer Prevention
- Sequential Use of the Androgen Synthesis Inhibitors Ketoconazole and Abiraterone Acetate in Castration-Resistant Prostate Cancer and the Predictive Value of Circulating Androgens
- (2014) W. Kim et al. CLINICAL CANCER RESEARCH
- Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer
- (2014) P. J. Toren et al. MOLECULAR CANCER THERAPEUTICS
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Castration-resistant prostate cancer: latest evidence and therapeutic implications
- (2014) Daniel L. Suzman et al. Therapeutic Advances in Medical Oncology
- Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer
- (2013) Lina Yin et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Abstract 7: Knockdown ofEGFRto investigate its therapeutic potential for treatment of non-small cell lung cancers
- (2012) Junichi Soh et al. CANCER RESEARCH
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial
- (2012) Matthew R Sydes et al. Trials
- Development and Clinical Utility of Abiraterone Acetate as an Androgen Synthesis Inhibitor
- (2011) A Bryce et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): Head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model
- (2011) Robert D. Bruno et al. STEROIDS
- Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy
- (2010) Charles J. Ryan et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
- (2010) Daniel C. Danila et al. JOURNAL OF CLINICAL ONCOLOGY
- CYP17 inhibitors for prostate cancer therapy
- (2010) Tadas S. Vasaitis et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven
- (2008) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen receptor inactivation contributes to antitumor efficacy of 17 -hydroxylase/17,20-lyase inhibitor 3 -hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer
- (2008) T. Vasaitis et al. MOLECULAR CANCER THERAPEUTICS
- Cytochrome P450 and Chemical Toxicology
- (2007) F. Peter Guengerich CHEMICAL RESEARCH IN TOXICOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started